Recent News / Read More
TWi Biotechnology, Inc. Announces First Patient Enrolled in Phase 2/3 Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa Simplex
TWi Biotechnology, Inc. (6610 TWO), a clinical stage biotechnology company specializing in the development of repositioned drugs for unmet medical needs, announced that on April 4, 2024, the first patient was dosed in its phase 2/3 trial of AC-203 for the treatment of generalized epidermolysis bullosa simplex (EBS) at Premier Specialists Pty Ltd in Australia. 2023-06-06TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)
Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments 2021-06-28Inmagene and TWIB Partner to Develop AC-1101 for Multiple Dermatological Immunological Diseases
Inmagene and TWIB Partner to Develop AC-1101 for Multiple Dermatological Immunological Diseases 2021-01-07【PR Newswire】Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203
Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases. 
Focus on TWi Biotechnology
TWi Biotechnology, Inc (TWi Biotechnology) is a clinical stage biopharmaceutical company based in Taipei, Taiwan.
Established in July 2010, TWi Biotechnology is dedicated to developing new drugs for innate immunity-related diseases, including diabetes mellitus, gout, ophthalmic and dermal conditions, and others. With its extensive experience in clinical, pre-clinical, animal pharmacology/toxicology studies, domestic and international regulatory standards, and deep knowledge in international patent protection and the specialty drug market in the US, TWi Biotechnology is in a leading position to develop new treatments in these therapeutic areas.
AC-1101
AC-1101 is a proprietary topical gel formulation of the small molecule Janus kinase (JAK) inhibitor being developed for the treatment of autoimmune inflammatory skin diseases.
Read MoreAC-203
AC-203 is a proprietary topical formulation of AC-201, which has been shown to inhibit the activity of caspase-1 and production of cytokine Interleukin-1Beta (IL-1Beta) through inhibition of theNLRP3 inflammasome activation. Blockade of the NLRP3 inflammasome-associated signaling pathway and subsequent IL-1Beta roduction has been demonstrated to be effective in treating a variety of diseases including arthritis, gout, and diabetes mellitus (DM).
Read MoreEpidermolysis bullosa
Epidermolysis bullosa (EB) is a group of genetic conditions that result in easy blistering of the skin and mucous membranes. Blisters occur with minor trauma or friction and are painful.
Read MoreRecent treatment
Company treatment field
